
Palisades Therapeutics Unveils Breakthrough Multi-Mechanistic Data for PT150 and PT157 in Resistant Cancers
Dual AR/GR Antagonism, Metabolic Reprogramming, and Lysosomal Bypass Position PT150 and PT157 as Best-in-Class Oncology Candidates CLIFFSIDE PARK, NJ, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Pop Test Oncology LLC dba Palisades …